Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.57 |
| ▸ | FAAH | O00519 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16244201 | 1.00 | CYP1A2 (0.57) | CYP1A2FAAHCYP3A4CYP2C19SOAT1 | |
| SCHEMBL3338606 | 0.83 | PPARG (0.57) | CYP1A2FAAHCYP2C19KMT2AALDH1A1 | |
| SCHEMBL9881033 | 0.83 | TRPV1 (0.44) | CYP1A2FAAHCYP3A4CYP2C19SOAT1 | |
| SCHEMBL2208064 | 0.83 | PPARG (0.57) | CYP1A2FAAHCYP2C19KMT2AALDH1A1 | |
| SCHEMBL2208066 | 0.83 | PPARG (0.57) | CYP1A2FAAHCYP2C19KMT2AALDH1A1 | |
| SCHEMBL22620633 | 0.82 | TRPV1 (0.42) | CYP1A2FAAHCYP3A4CYP2C19SOAT1 | |
| SCHEMBL2208737 | 0.82 | PPARG (0.60) | CYP1A2FAAHCYP3A4CYP2C19MEN1 | |
| SCHEMBL3436993 | 0.82 | TRPV1 (0.43) | CYP1A2FAAHCYP3A4CYP2C19SOAT1 | |
| SCHEMBL22555583 | 0.82 | PPARG (0.60) | CYP1A2FAAHCYP3A4CYP2C19MEN1 | |
| SCHEMBL2206758 | 0.82 | PPARG (0.60) | CYP1A2FAAHCYP3A4CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| CN-116640093-A | Capsaicin-tacrine hybrid, and preparation method and application thereof | 广西医科大学第一附属医院 | 2023-08-25 | — | — | CN | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| CN-111511402-A | Agent for preventing and/or treating cataract, pharmaceutical composition for preventing and/or treating cataract, use of PPAR activator for producing the same, and eye drop | 国立大学法人福井大学 | 2020-08-07 | — | — | CN | disclosed |
| US-20080008988-A1 | Compositions and methods for diagnosis of axial pain with or without radiculopathy | MEDTRONIC, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | CYP1A2 3413/4885FAAH 608/4885CYP3A4 2859/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | CYP1A2 3413/4885FAAH 608/4885CYP3A4 2859/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | CYP1A2 2879/4885FAAH 483/4885CYP3A4 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.